‘At The End Of The Day, It’s A Huge, Huge Opportunity’ – Teva’s Rainey Talks Stelara

Tom Rainey, SVP Of US Market Access At Teva, Discusses The Firm’s US Biosimilars Business

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.